Research programme: retroviral non-replicating vector based cancer immunotherapy - TocagenAlternative Names: TOCA 621; Toca Gamma
Latest Information Update: 18 Mar 2014
At a glance
- Originator Viagene Biotech
- Developer Tocagen
- Class Gene therapies
- Mechanism of Action Gene transference; Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer
- No development reported Malignant melanoma
Most Recent Events
- 13 Jul 2010 Preclinical trials in Malignant melanoma in USA (Parenteral)